Navigation Links
GSK Announces Changes to Corporate Executive Team

PHILADELPHIA and LONDON, April 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced a number of changes to its Corporate Executive management team. In a message to employees, Andrew Witty, CEO designate, detailed new appointments and his new management team which will take effect on May 22nd when he assumes the role of Chief Executive Officer.

Outlining the context for these changes, Andrew Witty said: "It is clear that our industry is facing a rapidly changing environment. Demand for innovative medicines and healthcare products continues to grow, however we are also presented with increasing challenges, such as cost containment, regulatory pressures and generic competition."

To address these challenges, Witty stated that the company must work hard to increase GSK's global reach and presence, and ensure that vaccines, consumer healthcare and pharmaceuticals all play their full potential. He emphasized the need for GSK's business regions to drive sales growth, and announced new operational structures to expand and improve GSK's capability, particularly in emerging markets and in Asia.

"Emerging markets, such as Brazil, Russia, India, China and the Middle East, are significant growth drivers of the future. They are already contributing close to 25% of today's market growth and are forecast to grow even faster in the future, around triple the rate of western countries. It is essential that we have an operating structure that is dynamic and responsive to the opportunities in these markets," said Witty.

"I am therefore creating a new Emerging Markets region which will ensure that we devote the focus required to build on our excellent foundations in those markets and truly establish ourselves as a trusted, long-term partner, one that is actively working to address the specific healthcare needs in those countries," he said.

A new Asia Pacific region will also be created, which includes Japan and Australia. Witty noted that many of these countries have sophisticated and well-organized healthcare systems and that these markets represent "significant and immediate opportunities" for existing products and products which will be launched over the next few years.

As part of the changes to business regions, GSK has also realigned markets in North America (combining the US, Canadian and Puerto Rican businesses) and has established new operational areas in Europe to maximize their potential and opportunities for growth.

Witty also placed emphasis on the development of GSK's business through partnership and collaboration, and announced a new dedicated team for Corporate Strategy and Development:

"Making the changes required to develop our business for the next decade requires a rigorous and disciplined focus on corporate strategy. A key element of this new team's remit will be to proactively seek new business opportunities to expand our global reach and drive sales growth," he said. Finally, Witty also spoke to measures to improve processes and ensure that the company works effectively and efficiently. He also placed great emphasis on the need to sustain and develop the strong ethical culture of GSK:

"Ultimately, our culture and our people will be the key factors in our success. We need to ensure that we always do what is right for the patients and I want GSK to meet the highest standards expected of us by society," said Witty.

GSK Corporate Executive Team (effective May 22nd 2008):

-- Andrew Witty, Chief Executive Officer*

-- Julian Heslop, Chief Financial Officer*

-- Moncef Slaoui, Chairman, Research & Development*

-- Chris Viehbacher, President, North American Pharmaceuticals*

-- Simon Bicknell, SVP, Company Secretary & Compliance Officer

-- John Clarke, President, Consumer Healthcare

-- Marc Dunoyer, President, Asia Pacific

-- Eddie Gray, President, Pharmaceuticals Europe

-- Abbas Hussain, President, Emerging Markets. Abbas will join GSK on 2

June from Eli Lilly and Company, where he has spent 20 years overseeing

markets throughout Europe, Africa/Middle East and Australasia

-- Duncan Learmouth, SVP, Corporate Communications & Global Community


-- Bill Louv, Chief Information Officer

-- Dan Phelan, Chief of Staff

-- David Pulman, President, Global Manufacturing & Supply

-- David Redfern, Chief Strategy Officer

-- Jean Stephenne, President and General Manager, Biologicals

-- Claire Thomas, SVP, Human Resources

-- SVP & General Counsel (currently vacant)

* Executive directors who are also members of GSK's Board of Directors

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Summit VetPharm Announces New Distributor Partnership with Webster Veterinary
2. Psychemedics Corporation Announces First Quarter Results
3. InfoLogix Announces First Quarter 2008 Financial Results
4. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
5. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
6. ATS Medical Announces First Frontiers in Cryoablation Symposium
7. Carriage Services Announces First Quarter Earnings Release and Conference Call Schedule
8. Warner Chilcott Announces Settlement of Securities Litigation
9. SXC Health Solutions announces completion of exchange offer for NMHC
10. Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes
11. WellPoint Announces Acquisition of DeCare Dental
Post Your Comments:
(Date:10/9/2015)... ... 09, 2015 , ... A new health tool that helps identify if a ... ( ) – just in time for the cold and flu season, which ... for many in the U.S., the real start of cold/flu season is the start ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington Beach ... system that uses clear, plastic aligners. This alternative to braces has become wildly ... allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Asthma ... the US Centers for Disease Control and Prevention (CDC) to improve the knowledge and ... that AAFA has been awarded a project by the CDC and allows AAFA to ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... individuals from all walks of life to save money on the high cost ... $25 per month per medication, individuals and families can receive their medications delivered ...
(Date:10/9/2015)... ... October 09, 2015 , ... Ryan Fox, ... largest recreational dispensaries in Colorado, says the latest figures on the state’s sales ... maturing into a legitimate industry. , Last month, according to the ...
Breaking Medicine News(10 mins):
... ... Integration project team including Drummond Group Inc., the trusted interoperability test lab, to conduct a ... project and leading the testing efforts with strong support from the project stakeholders. ... Austin, TX (PRWEB) December 7, ...
... ... medical research. , ... AZ (PRWEB) December 7, 2009 -- is doing its part to help find a ... Cure Catheters to its list of nearly 45,000 products., , ,Cure Medical is a forward-thinking ...
... , NEW ORLEANS, Dec. 7 ... Ruth Pettengell, M.D. of St. George,s Hospital, University of London during ... Meeting updated results from the pivotal phase III EXTEND (PIX 301) ... or refractory, aggressive non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
... , OAK BROOK, Ill., Dec. ... academic medical center (AMC) members for their achievements in ... 10 organizations are noted for modeling best practices in ... ) , The winners were determined using 2008 ...
... the loss of a key segment of DNA can lead to ... this kind of genetic alteration can cause obesity. The results are ... Dr Sadaf Farooqi from the University of Cambridge and Dr Matt ... with severe obesity. The team scanned each child,s entire genome ...
... Dec. 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... 003-A1 study, known as the 003 trial, demonstrating that carfilzomib ... patients. These data were presented today at the ASH/ASCO Joint ... of Hematology (ASH) in New Orleans. Enrollment in this trial ...
Cached Medicine News:
(Date:10/9/2015)... DIEGO , Oct. 9, 2015 Ansun ... (Infectious Disease Society of America ) regarding the compassionate ... transplant patient on a respirator who was co-infected with ... a five-day course of therapy, O 2 requirement ... the patient was able to go off the respirator ...
(Date:10/8/2015)... October 9, 2015 ® ... diagnostic colonoscopy. The NOCT study also assessed the ... --> ® ) in adult patients ... study also assessed the compliance, safety, patient acceptability ... today announced positive top line results for its ...
(Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015 /PRNewswire/ ... pharmaceutical company, will host a conference call and webcast ... ET to review the value to be created for ... TASE) through Mylan,s offer to acquire the company. During ... outlines the compelling proposition for Perrigo shareholders. Mylan,s offer ...
Breaking Medicine Technology:
... IDEV Technologies, Inc. (IDEV) today announced the firm ... Australia,s regulatory agency for medical drugs and devices, for ... and peripheral procedures. "We are pleased to ... SUPERA VERITAS in the Australian market later this year," ...
... 28, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the ... Paris, France. "The data we are ... an important new treatment option for patients with multiple ...
Cached Medicine Technology:
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Handheld Digital Retinal Camera...
Medicine Products: